| Assay ID | Title | Year | Journal | Article |
|---|
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
| Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1
| High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
| Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1
| High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
| Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1
| High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | | | |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | | | |
| AID1693837 | Inhibition of human CD73 | 2021 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 34 | Discovery of natural product ellagic acid as a potent CD73 and CD39 dual inhibitor. |
| AID1605341 | Activation of recombinant human P2Y12 receptor expressed in CHOK1 cells assessed as stimulation of calcium mobilization at 10 uM incubated for 90 mins by luminescence based assay | 2020 | Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6
| 2-Substituted α,β-Methylene-ADP Derivatives: Potent Competitive Ecto-5'-nucleotidase (CD73) Inhibitors with Variable Binding Modes. |
| AID1819265 | Inhibition of 5'-Nucleotidase activity in human HN-SCC cells assessed as reduction in tumor CD73 catalytic activity incubated for 45 mins in presence of Pb(NO3)2 by H and E staining based assay | 2022 | Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
| Structure-Activity Relationship of 3-Methylcytidine-5'-α,β-methylenediphosphates as CD73 Inhibitors. |
| AID1606468 | Inhibition of human CD73 | 2020 | Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8
| Discovery of Potent and Selective Non-Nucleotide Small Molecule Inhibitors of CD73. |
| AID440574 | Binding affinity to Mycobacterium tuberculosis adenosine-5'-phosphosulfate reductase assessed as S-sulfocysteine formation at pH 5.5 by single turnover method in absence of thioredoxin | 2009 | Journal of medicinal chemistry, Sep-10, Volume: 52, Issue:17
| Identification of critical ligand binding determinants in Mycobacterium tuberculosis adenosine-5'-phosphosulfate reductase. |
| AID1693839 | Inhibition of mouse CD39 | 2021 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 34 | Discovery of natural product ellagic acid as a potent CD73 and CD39 dual inhibitor. |
| AID1692592 | Inhibition of human C-terminal His6-tagged CD73 expressed in HEK293F cells using [15N]5-AMP as substrate preincubated for 1 hr followed by substrate addition and measured after 8 mins by MS/MS assay | 2020 | Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
| Targeting Metabolism of Extracellular Nucleotides via Inhibition of Ectonucleotidases CD73 and CD39. |
| AID1605343 | Metabolic stability in rat liver microsomes assessed as compound degradation at 200 uM after 30 mins in presence of NADPH regenerative system at 37 degC by LC-MS analysis | 2020 | Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6
| 2-Substituted α,β-Methylene-ADP Derivatives: Potent Competitive Ecto-5'-nucleotidase (CD73) Inhibitors with Variable Binding Modes. |
| AID1889905 | Inhibition of CD73 (unknown origin) | 2022 | Bioorganic & medicinal chemistry, 04-01, Volume: 59 | Discovery and optimization of betulinic acid derivatives as novel potent CD73 inhibitors. |
| AID1605342 | Metabolic stability in human blood plasma assessed as compound degradation at 200 uM incubated for 5 hrs at 37 degC by LC-MS analysis | 2020 | Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6
| 2-Substituted α,β-Methylene-ADP Derivatives: Potent Competitive Ecto-5'-nucleotidase (CD73) Inhibitors with Variable Binding Modes. |
| AID1692594 | Inhibition of rat CD73 expressed in baculovirus infected insect cells using AMP substrate by capillary electrophoresis assay | 2020 | Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
| Targeting Metabolism of Extracellular Nucleotides via Inhibition of Ectonucleotidases CD73 and CD39. |
| AID1408359 | Inhibition of recombinant CD73 (27 to 549 residues) (unknown origin) expressed in baculovirus infected Sf9 insect cells assessed as reduction in conversion of AMP to adenosine incubated for 1 min followed by AMP addition measured after 3.5 mins by malachi | 2018 | European journal of medicinal chemistry, Sep-05, Volume: 157 | CD73 inhibition by purine cytotoxic nucleoside analogue-based diphosphonates. |
| AID1692589 | Inhibition of recombinant human CD73 using AMP as substrate incubated for 90 mins by malachite green colorimetric assay | 2020 | Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
| Targeting Metabolism of Extracellular Nucleotides via Inhibition of Ectonucleotidases CD73 and CD39. |
| AID1605340 | Activation of recombinant human P2Y1 receptor expressed in human 1321N1 cells assessed as stimulation of calcium mobilization at 10 uM by fluorescence based assay | 2020 | Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6
| 2-Substituted α,β-Methylene-ADP Derivatives: Potent Competitive Ecto-5'-nucleotidase (CD73) Inhibitors with Variable Binding Modes. |
| AID1889898 | Inhibition of human CD73 assessed as reduction in inorganic phosphate release upon substrate hydrolysis using AMP/ATP as substrate incubated for 1 hr followed by substrate addition and measured after 2 hrs by malachite green reagent based colorimetric ass | 2022 | Bioorganic & medicinal chemistry, 04-01, Volume: 59 | Discovery and optimization of betulinic acid derivatives as novel potent CD73 inhibitors. |
| AID1593549 | Inhibition of recombinant rat C-terminal His-tagged soluble form of CD73 expressed in baculovirus infected Sf9 insect cells at 1 uM using [2,8-3H]AMP as substrate measured after 25 mins by scintillation counting method relative to control | 2019 | Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
| Structure-Activity Relationship of Purine and Pyrimidine Nucleotides as Ecto-5'-Nucleotidase (CD73) Inhibitors. |
| AID1408361 | Inhibition of CD73 in human NCI-H292 cells assessed as reduction in conversion of AMP to adenosine incubated for 30 mins by malachite green reagent based assay | 2018 | European journal of medicinal chemistry, Sep-05, Volume: 157 | CD73 inhibition by purine cytotoxic nucleoside analogue-based diphosphonates. |
| AID1693838 | Inhibition of mouse CD73 | 2021 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 34 | Discovery of natural product ellagic acid as a potent CD73 and CD39 dual inhibitor. |
| AID1593548 | Inhibition of recombinant rat C-terminal His-tagged soluble form of CD73 expressed in baculovirus infected Sf9 insect cells using [2,8-3H]AMP as substrate measured after 25 mins by scintillation counting method | 2019 | Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
| Structure-Activity Relationship of Purine and Pyrimidine Nucleotides as Ecto-5'-Nucleotidase (CD73) Inhibitors. |
| AID1605334 | Inhibition of purified recombinant soluble human CD73 expressed in Sf9 cells [3H]AMP as substrate incubated for 25 mins by scintillation counting method | 2020 | Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6
| 2-Substituted α,β-Methylene-ADP Derivatives: Potent Competitive Ecto-5'-nucleotidase (CD73) Inhibitors with Variable Binding Modes. |
| AID1724308 | Inhibition of CD73 in human NCI-H1568 cells assessed as reduction in AMP-induced ADO expression preincubated for 15 mins followed by AMP addition and measured after 1 hr by LC-MS/MS analysis | | | |
| AID1724307 | Inhibition of human C-terminal His6-tagged CD73 expressed in CHO cells preincubated for 15 mins followed by AMP addition and measured after 10 mins by malachite green reagent based assay | | | |
| AID1819266 | Inhibition of 5'-Nucleotidase activity in human tonsils assessed as reduction in CD73 catalytic activity in tonsils incubated for 45 mins in presence of Pb(NO3)2 by H and E staining based assay | 2022 | Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
| Structure-Activity Relationship of 3-Methylcytidine-5'-α,β-methylenediphosphates as CD73 Inhibitors. |
| AID1889899 | Inhibition of mouse CD73 assessed as reduction in inorganic phosphate release upon substrate hydrolysis using AMP/ATP as substrate incubated for 1 hr followed by substrate addition and measured after 2 hrs by malachite green reagent based colorimetric ass | 2022 | Bioorganic & medicinal chemistry, 04-01, Volume: 59 | Discovery and optimization of betulinic acid derivatives as novel potent CD73 inhibitors. |
| AID1415776 | Competitive-inhibition of recombinant human N-terminal His-tagged soluble NPP1 (Val191 to Leu591 residues) expressed in mouse NSO cells using ATP as substrate by capillary electrophoresis method | 2017 | MedChemComm, May-01, Volume: 8, Issue:5
| Nucleotide pyrophosphatase/phosphodiesterase 1 (NPP1) and its inhibitors. |
| AID1415779 | Competitive-inhibition of recombinant human N-terminal His-tagged soluble NPP1 (Val191 to Leu591 residues) expressed in mouse NSO cells using p-Nph-5'-AMP as substrate after 30 mins by capillary electrophoresis method | 2017 | MedChemComm, May-01, Volume: 8, Issue:5
| Nucleotide pyrophosphatase/phosphodiesterase 1 (NPP1) and its inhibitors. |
| AID1692590 | Inhibition of recombinant human CD73 using AMP as substrate incubated for 120 mins by CellTiter-Glo assay | 2020 | Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
| Targeting Metabolism of Extracellular Nucleotides via Inhibition of Ectonucleotidases CD73 and CD39. |
| AID1692595 | Inhibition of CD73 in human melanoma 1539 cells using AMP substrate by capillary electrophoresis assay | 2020 | Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
| Targeting Metabolism of Extracellular Nucleotides via Inhibition of Ectonucleotidases CD73 and CD39. |
| AID1415784 | Competitive-inhibition of recombinant human NPP1 expressed in HEK293 cell membranes using p-Nph-5'-TMP as substrate pretreated for 10 mins followed by substrate addition and measured after 60 mins by capillary electrophoresis method | 2017 | MedChemComm, May-01, Volume: 8, Issue:5
| Nucleotide pyrophosphatase/phosphodiesterase 1 (NPP1) and its inhibitors. |
| AID1819262 | Inhibition of human recombinant soluble CD73 assessed as inhibition constant by radiometric assay | 2022 | Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
| Structure-Activity Relationship of 3-Methylcytidine-5'-α,β-methylenediphosphates as CD73 Inhibitors. |
| AID1408360 | Inhibition of CD73 in human MDA-MB-231 cells assessed as reduction in conversion of AMP to adenosine incubated for 30 mins by malachite green reagent based assay | 2018 | European journal of medicinal chemistry, Sep-05, Volume: 157 | CD73 inhibition by purine cytotoxic nucleoside analogue-based diphosphonates. |
| AID1889901 | Induction of anti-CD3/CD28 antibodies-stimulated CD4-positive Th cell activation in C57BL/6J mouse assessed as reversal of AMP/EHNA-inhibited IFN-gamma production at 10 uM preincubated for 15 mins followed by AMP/EHNA addition and measured after 96 hrs by | 2022 | Bioorganic & medicinal chemistry, 04-01, Volume: 59 | Discovery and optimization of betulinic acid derivatives as novel potent CD73 inhibitors. |
| AID1415786 | Mixed-inhibition of Wistar rat NPP1 using p-Nph-5'-TMP as substrate measured after 5 mins by UPLC method | 2017 | MedChemComm, May-01, Volume: 8, Issue:5
| Nucleotide pyrophosphatase/phosphodiesterase 1 (NPP1) and its inhibitors. |
| AID1605335 | Inhibition of native CD73 in human MDA-MB-231 cell membrane preparations [3H]AMP as substrate incubated for 25 mins by scintillation counting method | 2020 | Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6
| 2-Substituted α,β-Methylene-ADP Derivatives: Potent Competitive Ecto-5'-nucleotidase (CD73) Inhibitors with Variable Binding Modes. |
| AID1415777 | Competitive-inhibition of recombinant human N-terminal His-tagged soluble NPP1 (Val191 to Leu591 residues) expressed in mouse NSO cells using ATP as substrate after 30 mins by capillary electrophoresis method | 2017 | MedChemComm, May-01, Volume: 8, Issue:5
| Nucleotide pyrophosphatase/phosphodiesterase 1 (NPP1) and its inhibitors. |
| AID1415778 | Competitive-inhibition of recombinant human N-terminal His-tagged soluble NPP1 (Val191 to Leu591 residues) expressed in mouse NSO cells using p-Nph-5'-TMP as substrate after 15 mins by capillary electrophoresis method | 2017 | MedChemComm, May-01, Volume: 8, Issue:5
| Nucleotide pyrophosphatase/phosphodiesterase 1 (NPP1) and its inhibitors. |
| AID1674319 | Inhibition of human CD73 using AMP as substrate by Malachite green phosphate reagent-based assay | 2020 | Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20
| Discovery of AB680: A Potent and Selective Inhibitor of CD73. |
| AID1692593 | Inhibition of human CD73 expressed in CHO cells using AMP as substrate preincubated for 10 mins followed by substrate addition and measured every minute for 10 to 20 mins by PNP coupled enzyme assay | 2020 | Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
| Targeting Metabolism of Extracellular Nucleotides via Inhibition of Ectonucleotidases CD73 and CD39. |
| AID1605333 | Inhibition of purified recombinant soluble rat CD73 expressed in Sf9 cells [3H]AMP as substrate incubated for 25 mins by scintillation counting method | 2020 | Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6
| 2-Substituted α,β-Methylene-ADP Derivatives: Potent Competitive Ecto-5'-nucleotidase (CD73) Inhibitors with Variable Binding Modes. |
| AID1593546 | Inhibition of CD73 in human tonsils at 100 nM using AMP as substrate preincubated for 30 mins followed by substrate addition and measured after 45 mins by lead nitrate-based histochemical analysis | 2019 | Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
| Structure-Activity Relationship of Purine and Pyrimidine Nucleotides as Ecto-5'-Nucleotidase (CD73) Inhibitors. |
| AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4
| A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
| AID1347154 | Primary screen GU AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1797699 | In Vitro Enzyme Activity Assay from Article 10.1021/bi030031h: \\Thermodynamic characterization of the binding of nucleotides to glycyl-tRNA synthetase.\\ | 2003 | Biochemistry, May-13, Volume: 42, Issue:18
| Thermodynamic characterization of the binding of nucleotides to glycyl-tRNA synthetase. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |